Farmas USA

BIIB

Si nos fiamos del pre-market, al mercado ni fu ni fa... medio punto pa'rriba a esta hora.

NVAX

2015 Annual Report
http://www.envisionreports.com/NVAX/2016/26F18MA16E/74bd8dcd2b4645c7884c1895a6701106/Novavax_AR_04-25-16_secured.pdf

NVAX

Uf, qué tocho. Yo ya voté hace días: que sí a todo menos a la emisión de los 6 millones de acciones.

Malo malo el pre de HZNP.

Mihuzo acaba de hacerle downgrade 34$ a 25$

HZNP

Vuelvo a mirar el grafico, retiro lo dicho antes, no se porque recordaba los 14,8 como zona que me gustaba de compra, quizas por grafico intradiario lo dije, pero bueno, por diario asi va la cosa. No tengo cash pero hasta despues de earnings no la tocare aunque me haga con liquidez.

Como animan a AMRN las opciones de este viernes, esas call a $2 ... 

Noticias del sector del día

Billionaires Warren Buffett and Bill Ackman couldn't be further apart on Valeant Pharmaceuticals (NYSE:VRX). In back-to-back television interviews, Buffett lambasted the embattled firm over its price increases and business practices, building on his deputy Charles Munger's weekend comments, which called the drugmaker "a sewer." The business "makes a lot of very good products," Ackman said in response. "It is not fair to indict an entire company based on the actions of a few

Following a three-week trial in Missouri, Johnson & Johnson (NYSE:JNJ) has been ordered to pay $55M to a woman who said that using the company’s talc-powder products for feminine hygiene caused her to develop ovarian cancer. The verdict, which J&J plans to appeal, was the second straight trial loss for the company, which is facing about 1,200 lawsuits accusing it of not adequately warning consumers about talc-based cancer risks.

http://seekingalpha.com/news/3178392-johnson-and-johnson-ordered-pay-55m-new-talc-verdict?ifp=0

Nvax
!vaya ensalada de precios! Eso sí, la media es cojonuda !gracias David! Jaja.